As reported in WMS, Kathy Miska was beginning to have difficulty walking. This time, she knew what was happening. She'd seen the same thing happen to her sister, who went…
As reported in Biospace, Adverum Biotechnologies, a gene therapy company focused on clinical stage trials for rare and ocular diseases with unmet needs, has successfully dosed a patient in their…
According to Juvenile Arthritis News, treating juvenile idiopathic arthritis early helps reduce symptoms, nearly "inactivating" the condition. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry found that early…
The European Commission has just granted their approval to Pharming for an extended indication of RUCONEST (conestat alfa) for Hereditary Angioedema (HAE). This extension allows the therapy to be utilized for…
A New Study A new study, conducted by CLS Behring, has found that a new method of administration for Hizentra as a treatment for primary immunodeficiency (PI), could improve quality…
According to a story from abc7.com, a recent case study has identified what scientists believe to be the earliest case of a pediatric COVID-19 patient presenting with symptoms of pediatric…
If you're like me, you've been refreshing the news every day trying to find more information on COVID-19. After all, life changed in March; the global pandemic and its associated…
According to a press release from PR Newswire and GuruFocus, drug discovery and development company Sutro Biopharma received promising phase 1 clinical data for their drug therapy STRO-002. Their Phase…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
